Skip to main content

Advertisement

SpringerLink
Log in

Lipids and diabetic renal disease

  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Diabetic nephropathy is commonly associated with dyslipidemia, but the role of lipids in the progression of this disorder remains unresolved. In particular, the role of lipid-lowering drugs, such as 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and fibrates, as renoprotective agents is not clarified. Experimental studies have demonstrated that dietary lipids promote renal injury and that statins, independent of their lipid-lowering effects, confer renoprotection via effects on intrarenal hemodynamics and renal cytokine and chemokine expression. Clinical studies have in general been underpowered, but a recent meta-analysis and findings from the Heart Protection Study suggest that statins may be renoprotective. Nevertheless, with the convincing antiatherosclerotic effects of these agents, including in the setting of diabetes, they should be widely administered in the diabetic population with or at risk for nephropathy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Grone HJ, Walli AK, Grone E, et al.: Receptor mediated uptake of apo B and apo E rich lipoproteins by human glomerular epithelial cells. Kidney Int 1990, 37:1449–1459.

    PubMed  CAS  Google Scholar 

  2. Takemura T, Yoshioka K, Aya N, et al.: Apolipoproteins and lipoprotein receptors in glomeruli in human kidney diseases. Kidney Int 1993, 43:918–927.

    PubMed  CAS  Google Scholar 

  3. Grone HJ, Walli AK, Grone EF: The role of oxidatively modified lipoproteins in lipid nephropathy. Contrib Nephrol 1997, 120:160–175.

    PubMed  CAS  Google Scholar 

  4. Lassila M, Jandeleit-Dahm K, Seah KK, et al.: Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol 2002, 16:363–373.

    Article  CAS  Google Scholar 

  5. French SW, Yamanaka W, Ostwald R: Dietary induced glomerulosclerosis in the guinea pig. Arch Pathol 1967, 83:204–210.

    PubMed  CAS  Google Scholar 

  6. Wellmann KF, Volk BW: Renal changes in experimental hypercholesterolemia in normal and in subdiabetic rabbits. II. Long-term studies. Lab Invest 1971, 24:144–155.

    PubMed  CAS  Google Scholar 

  7. Peric-Golia L, Peric-Golia M: Aortic and renal lesions in hypercholesterolemic adult, male, virgin Sprague-Dawley rats. Atherosclerosis 1983, 46:57–65.

    Article  PubMed  CAS  Google Scholar 

  8. Kasiske BL, O’Donnell MP, Schmitz PG, et al.: Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int 1990, 37:880–891.

    PubMed  CAS  Google Scholar 

  9. Bank N, Aynedjian HS: Role of thromboxane in impaired renal vasodilatation response to acetylcholine in hypercholesterolemic rats. J Clin Invest 1992, 89:1636–1642.

    PubMed  CAS  Google Scholar 

  10. Zatz R, Dunn BR, Meyer TW, et al.: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986, 77:1925–1930.

    PubMed  CAS  Google Scholar 

  11. Gilbert RE, Cooper ME: The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 1999, 56:1627–1637.

    Article  PubMed  CAS  Google Scholar 

  12. Grone HJ, Hohbach J, Grone EF: Modulation of glomerular sclerosis and interstitial fibrosis by native and modified lipoproteins. Kidney Int Suppl 1996, 54:S18-S22.

    PubMed  CAS  Google Scholar 

  13. Remuzzi G, Ruggenenti P, Benigni A: Understanding the nature of renal disease progression. Kidney Int 1997, 51:2–15.

    Article  PubMed  CAS  Google Scholar 

  14. Kasiske BL, O’Donnell MP, Cleary MP, Keane WF: Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 1988, 33:667–672.

    PubMed  CAS  Google Scholar 

  15. Kasiske BL, O’Donnell MP, Garvis WJ, Keane WF: Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res 1988, 62:367–374.

    PubMed  CAS  Google Scholar 

  16. Jandeleit-Dahm K, Cao Z, Cox AJ, et al.: Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy. Kidney Int Suppl 1999, 71:S31–336.

    Article  PubMed  CAS  Google Scholar 

  17. Park YS, Guijarro C, Kim Y, et al.: Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. Am J Kidney Dis 1998, 31:190–194.

    PubMed  CAS  Google Scholar 

  18. Inman SR, Stowe NT, Cressman MD, et al.: Lovastatin preserves renal function in experimental diabetes. Am J Med Sci 1999, 317:215–221.

    Article  PubMed  CAS  Google Scholar 

  19. Kim SI, Han DC, Lee HB: Lovastatin inhibits transforming growth factor-beta1 expression in diabetic rat glomeruli and cultured rat mesangial cells. J Am Soc Nephrol 2000, 11:80–87. This study extends important mechanistic data on the link between statins and growth factors to the diabetic kidney.

    PubMed  CAS  Google Scholar 

  20. Blanco S, Vaquero M, Gomez-Guerrero C, et al.: Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension. Am J Hypertens 2005, 18:557–565. This recent paper describes effects of statins on the glomerular epithelial cell, a major focus of research in diabetic nephropathy.

    Article  PubMed  CAS  Google Scholar 

  21. Cooper ME, Mundel P, Boner G: Role of nephrin in renal disease including diabetic nephropathy. Semin Nephrol 2002, 22:393–398.

    Article  PubMed  CAS  Google Scholar 

  22. O’Donnell MP, Kasiske BL, Kim Y, et al.: Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest 1993, 91:83–87.

    Article  PubMed  CAS  Google Scholar 

  23. Casey RG, Joyce M, Roche-Nagle G, et al.: Pravastatin modulates early diabetic nephropathy in an experimental model of diabetic renal disease. J Surg Res 2005, 123:176–181.

    Article  PubMed  CAS  Google Scholar 

  24. Mulec H, Johnsen SA, Wiklund O, Bjorck S: Cholesterol: a renal risk factor in diabetic nephropathy? Am J Kidney Dis 1993, 22:196–201.

    PubMed  CAS  Google Scholar 

  25. Parving HH, Rossing P, Hommel E, Smidt UM: Angiotensinconverting enzyme inhibition in diabetic nephropathy: ten years’ experience. Am J Kidney Dis 1995, 26:99–107.

    PubMed  CAS  Google Scholar 

  26. Krolewski AS, Warram JH, Christlieb AR: Hypercholesterolemia —a determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int Suppl 1994, 45:S125-S131.

    PubMed  CAS  Google Scholar 

  27. Ravid M, Neumann L, Lishner M: Plasma lipids and the progression of nephropathy in diabetes mellitus type II: effect of ACE inhibitors. Kidney Int 1995, 47:907–910.

    PubMed  CAS  Google Scholar 

  28. Wirta OR, Pasternack AI, Mustonen JT, et al.: Urinary albumin excretion rate and its determinants after 6 years in noninsulin-dependent diabetic patients. Nephrol Dial Transplant 1996, 11:449–456.

    PubMed  CAS  Google Scholar 

  29. Viswanathan VV, Snehalatha C, Ramachandran A, Viswanathan M:Proteinuria in NIDDM in south India: analysis of predictive factors. Diabetes Res Clin Pract 1995, 28:41–46.

    Article  PubMed  CAS  Google Scholar 

  30. Oue T, Namba M, Nakajima H, et al.: Risk factors for the progression of microalbuminuria in Japanese type 2 diabetic patients--a 10 year follow-up study. Diabetes Res Clin Pract 1999, 46:47–55.

    Article  PubMed  CAS  Google Scholar 

  31. Coppelli A, Giannarelli R, Vistoli F, et al.: The beneficial effects of pancreas transplant alone on diabetic nephropathy. Diabetes Care 2005, 28:1366–1370. The authors provide evidence that some of the lipid abnormalities seen in diabetic nephropathy are reversible with restoration to normoglycemia.

    Article  PubMed  Google Scholar 

  32. Hommel E, Andersen P, Gall MA, et al.: Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia 1992, 35:447–451.

    Article  PubMed  CAS  Google Scholar 

  33. Fried LF, Orchard TJ, Kasiske BL: Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001, 59:260–269. This meta-analysis provides evidence that lipid-lowering treatment in diabetes, although inadequately tested in relatively small studies, is likely to be renoprotective.

    Article  PubMed  CAS  Google Scholar 

  34. Lam KS, Cheng IK, Janus ED, Pang RW: Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995, 38:604–609.

    PubMed  CAS  Google Scholar 

  35. Parving HH: Cholesterol-lowering therapy may retard the progression of diabetic nephropathy [letter]. Diabetologia 1996, 39:367–368.

    Article  PubMed  CAS  Google Scholar 

  36. Tonolo G, Ciccarese M, Brizzi P, et al.: Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care 1997, 20:1891–1895.

    Article  PubMed  CAS  Google Scholar 

  37. Zhang A, Vertommen J, Van Gaal L, De Leeuw I: Effects of pravastatin on lipid levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients. Diabetes Res Clin Pract 1995, 29:189–194.

    Article  PubMed  CAS  Google Scholar 

  38. Nielsen S, Schmitz O, Moller N, et al.: Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 1993, 36:1079–1086.

    Article  PubMed  CAS  Google Scholar 

  39. Smulders YM, van Eeden AE, Stehouwer CD, et al.: Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus?. Eur J Clin Invest 1997, 27:997–1002.

    Article  PubMed  CAS  Google Scholar 

  40. Nagai T, Tomizawa T, Nakajima K, Mori M: Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients. J Atheroscler Thromb 2000, 7:91–96.

    PubMed  CAS  Google Scholar 

  41. Collins R, Armitage J, Parish S, et al.: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005–2016. The Heart Protection Study provides convincing evidence that in a large population, including diabetic subjects, statin treatment appears to preserve renal function. These findings, not a primary aim of the study, need to be confirmed in a specifically designed large study where renal end points are the primary end points of the trial.

    Article  PubMed  Google Scholar 

  42. Athyros VG, Papageorgiou AA, Elisaf M, Mikhailidis DP: Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin 2003, 19:615–617.

    Article  PubMed  CAS  Google Scholar 

  43. Colhoun HM, Betteridge DJ, Durrington PN, et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685–696.

    Article  PubMed  CAS  Google Scholar 

  44. Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984, 310:356–360.

    Article  PubMed  CAS  Google Scholar 

  45. Gaede P, Vedel P, Larsen N, et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383–393.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. JDRF Danielle Alberti Memorial Centre for Diabetic Complications, Vascular Division - Wynn Domain, Baker Heart Research Institute, 75 Commercial Road, 3004, Melbourne, Victoria, Australia

    Mark E. Cooper MD, PhD

Authors
  1. Mark E. Cooper MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karin A. M. Jandeleit-Dahm MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cooper, M.E., Jandeleit-Dahm, K.A.M. Lipids and diabetic renal disease. Curr Diab Rep 5, 445–448 (2005). https://doi.org/10.1007/s11892-005-0053-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-005-0053-9

Keywords

Search

Navigation